New and emerging health technology reports
Recent publications from CCOHTA and other HTA agencies
As part of our horizon scanning we check the web sites of other HTA agencies for recent assessments that may be of interest to Canadian health care decision makers. Unless otherwise stated, these publications are available without cost at the web sites shown below.
Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)
Surgical treatment of morbid obesity: an update
Included is the latest evidence on different types of bariatric surgery used for the treatment of morbid obesity, with recommendations for the management of these surgical programs in Quebec. Available: http://www.aetmis.gouv.qc.ca/fr/publications/scientifiques/obesite/2005_04_res_en.pdf
Alberta Heritage Foundation for Medical Research (AHFMR)
Image-guided vacuum-assisted breast biopsy for suspicious, non-palpable breast lesions
An assessment of a less invasive approach to biopsy in the diagnosis of breast cancer. Available: http://www.ahfmr.ab.ca/download.php/0d7e234a84f703ed426fa9f37ecf236c
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
Cerebral protection devices for use during carotid artery stenting
These devices offer a new approach to reducing the risk of stroke or death in patients undergoing carotid artery angioplasty with stenting. Increased demand for this procedure, as an alternative to surgical carotid endarterectomy, may have a significant impact on health care costs and service delivery. Available: https://www.ccohta.ca/publications/pdf/360_cerebral_protection_devices_cetap_e.pdf
UK National Horizon Scanning Centre (NHSC)
FibroTest-ActiTest™ for diagnosis and monitoring of fibrosis in chronic liver conditions
The FibroTest-ActiTest is a non-invasive alternative to liver biopsy for patients with chronic hepatitis and other liver diseases. Available: http://pcpoh.bham.ac.uk/publichealth/horizon/PDF_files/2005reports/FibroTest_ActiTest.pdf
UK National Institute for Health and Clinical Excellence (NICE)
Cryotherapy as a primary treatment for prostate cancer
Current evidence supports the safety and effectiveness of cryotherapy as a primary treatment for prostate cancer, though further information on quality of life and long-term survival is needed. Available: http://www.nice.org.uk/pdf/ip/IPG145guidance.pdf